Ernexa Therapeutics ERNA
NASDAQ ERNA
$2.11 0.00 (-0.22%)
As of: Oct 22, 2026 · 2:46 PM EDT

Ernexa Therapeutics (ERNA) Cash from Restructuring (2021)

Updated

Ernexa Therapeutics' Cash from Restructuring came in at $5.77 million for FY2021.

Analysis

Ernexa Therapeutics (ERNA) Cash from Restructuring (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,170.23 Bn 1,138.82 Bn 19.71 Bn
2 Johnson & Johnson 648.85 Bn 568.71 Bn 17.30 Bn
3 AbbVie 504.91 Bn 478.02 Bn 12.70 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn
5 Novartis Ag 303.41 Bn 267.40 Bn 11.24 Bn
6 Astrazeneca 268.65 Bn 242.33 Bn 12.86 Bn
7 Amgen 242.96 Bn 198.36 Bn 7.24 Bn
8 Gilead Sciences 195.01 Bn 169.21 Bn 6.22 Bn
9 Pfizer 173.22 Bn 119.87 Bn 10.94 Bn
10 Ernexa Therapeutics 2.49 Mn -16.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 5.77 Mn
API Access

Ernexa Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ERNA&period=max&api_key=YOUR_API_KEY